Fig. 1: Mechanism of action of tafasitamab and lenalidomide. | Blood Cancer Journal

Fig. 1: Mechanism of action of tafasitamab and lenalidomide.

From: Diffuse large B-cell lymphoma: new targets and novel therapies

Fig. 1

Tafasitamab has been Fc enhanced to increase antibody-dependent cellular cytotoxicity (ADCC) which augments interactions with natural killer (NK) cells activated and expanded by lenalidomide, antibody-dependent cellular phagocytosis (ADCP) to enhance interactions with macrophages, and direct cell death.

Back to article page